$HEM volume increases
Hemostemix Inc. is a biotechnology company listed on TSX-V with ticker symbol $HEM has shown growth in its volume. Today the volume is 21.30K.
LongLong
Universal Ibogaine Market SummaryUniversal Ibogaine Inc. holds a significant position over the TSX-V market with its greater difference between the lower and higher ranges of trading, which is $0.04-$0.25 in the last 52 weeks.
Universal Ibogaine Stock SummaryUniversal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $139K+ in the last 3 months. The average volume of the company in the last 10 days is $81.88K with $190.74M share outstanding. The stock price when the market opened was $0.045.
UI CEO’s rapturous to work with Blue Digital Media"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
Dr. Sola's administration over 3700 Ibogaine Detox
Universal Ibogaine Co-Founder Dr Alberto Sola has administered over 3700 ibogaine detox treatments, more than any other doctor in the world.
Long
$HEM announced incorporation of an entirely owned subsidiary
The business is happy to announce that PreCerv Inc. ("PreCerv") has been incorporated as a completely owned subsidiary. A worldwide field of use licence for NCP-01 and its autologous stem cell technology will be acquired by PreCerv from Hemostemix.
Long
$IBO Stock Analysis GraphUniversal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of $172K+ in the last 3 months. The average volume of the company in the last 10 days is $97K with $190.16M share outstanding. The stock price when the market opened was $0.05.
$IBO shares trading unobstructed on the TSX-V$IBO is gliding swiftly on the TSX-V Index, the shares are trading currently at $0.05 which might get doubled in the upcoming days or week maximum.
$IBO CO-Founder with wide ranging work-experienceDr. Sola, a co-founder of Universal Ibogaine and a member of its Board of Directors, has effectively administered over 3,700 ibogaine treatments, more than any other doctor in the world, at an independent clinic in Cancun, Mexico, where he is a partner.
$IBO’S CEO comments on the H.C Wainwright"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
CEO highlights on the sheer extent of the research to reality ev"The significance of this occasion cannot be emphasized," said CEO Nick Karos. This is the first gathering of academic researchers, real-world technicians, and government policymakers of its sort. This event will raise awareness of ibogaine's great potential at the highest levels."
Universal Ibogaine Inc. CEO’s ecstatic to work with Blue Digital
"We are happy to have access to Blue Digital's distribution channels, as their range across borders will broaden awareness of our business to new audiences," said Nick Karos, UI's Chief Executive Officer. Because addiction knows no bounds, the remedy we seek must be global in scope." As Blue Digital Media professional radar.
Long
$HEM announcement related to the Stock Options GrantHemostemix Inc. announced that in accordance with its stock option plan, it has granted on February 28, 2022, subject to regulatory approval, a total of 1,494,269 stock options to purchase common shares of Hemostemix to directors, officers, employees and consultants of Hemostemix
Hemostemix Inc. Market Graph Hemostemix Inc. holds a significant role in TSX-V with its greater difference between the lower and higher range of trading today is $0.255-$0.285. In the last 52 weeks it is $0.13-$0.42.
$HEM- Market Opening ValueHemostemix Inc. is a publicly traded biotechnology company listed on TSX-V marked with an opening of $0.285.
$HEM volume increases Hemostemix Inc. is a biotechnology company listed on TSX-V with ticker symbol $HEM has shown growth in its volume. Today the volume is $8.62K.
$IBO announced a vital addition of clinical trials directorJulie Dumouchel has been named Director of Clinical Trials at UI, which is a significant strategic move. Julie Dumouchel has 25 years of experience in the pharmaceutical sector, where she has worked in a variety of clinical research jobs and has a thorough grasp of the drug development process.
Long
$IBO stock analysis
Universal Ibogaine Inc. is an expanding Canadian-holding company with an average volume of 138 K+ in the last 50 days . The average volume of the company in the last 10 days is $88.98K with $190.74M share outstanding. The stock price when the market opened was $0.05
Long
$IBOGF’s 52 week range dataUniversal Ibogaine Inc. is a life science company listed on OTC with the ticker symbol $IBOGF. In the last 52 weeks the range of the lower and upper price is $0.0258-$0.1143.
Universal Ibogaine Delivering Excellence The Company newly reported that its common shares, coined as "JC4", have been accepted for trade on the Frankfurt Stock Exchange, or Boerse Frankfurt. In Canada, UI will keep trading on the TSX Venture Exchange under the ticker IBO and on the OTCQB under the stock symbol IBOGF.
$IBO, Recognized as a powerful addiction interrupterOur mission is to redefine the addiction recovery experience, providing those living with addiction the best possible recovery.
While seeking to move Ibogaine through Clinical Trials in Canada, we are building a network of holistic recovery clinics and a state of the art treatment program centred around new treatment modalities.
$IBO to commission ultra- modern addiction treatment centre
At the Kelburn Clinic, UI is developing a cutting-edge holistic addiction treatment protocol that, when combined with the anticipated ibogaine detox programme, will transform the way we treat addiction and dramatically enhance the lives of individuals and families plagued by addiction.
Long
$IBO’S CEO comments on the H.C Wainwright
"H.C. Wainwright is a leader in the field and may be a significant strategic partner in our ongoing corporate finance roadmap," said Nick Karos, CEO of Universal Ibogaine. Another crucial step in raising awareness of our brand and service is the chance to share our story with this audience.
Long